Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Natalizumab (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms ACTION2
- Sponsors Biogen
- 24 Oct 2017 According to a Biogen media release, data is expected in early 2018.
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 28 Feb 2018.